Matrix metalloproteinase-2 is activated during ischemia/reperfusion in a model of myocardial infarction

Canadian Journal of Cardiology

Volumn 29, Issue 11, 2013, Pages 1495-1503

  Cadete, Virgilio J J ^a   Arcand, Steven A ^a   Chaharyn, Bradley M ^b   Doroszko, Adrian ^a   Sawicka, Jolanta ^a   Mousseau, Darrell D ^b   Sawicki, Grzegorz ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACTILE PROTEIN; GELATIN; GELATINASE A; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART PERFUSION; ISOLATED HEART; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PROTEIN DEGRADATION; RAT; REPERFUSION INJURY; ZYMOGRAPHY;

ANIMALS; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; ENZYME ASSAYS; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOSIN LIGHT CHAINS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84886946715     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.014     Document Type: Article

References (22)

1. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
2. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007, 47:211-242.
3. Cauwe B., Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010, 45:351-423.
4. Wang W., Schulze C.J., Suarez-Pinzon W.L., Dyck J.R., Sawick G., Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002, 106:1543-1549.
5. Ali M.A., Cho W.J., Hudson B., Kassiri Z., Granzier H., Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122:2039-2047.
6. Cadete V.J., Sawicka J., Jaswal J.S., et al. Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS J 2012, 279:2444-2454.
7. Doroszko A., Polewicz D., Sawicka J., Richardson J.S., Cheung P.Y., Sawicki G. Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2. Basic Res Cardiol 2009, 104:669-679.
8. Polewicz D., Cadete V.J., Doroszko A., et al. Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. JCell Mol Med 2011, 15:1136-1147.
9. Sawicki G., Leon H., Sawicka J., et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112:544-552.
10. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. JBiol Chem 1996, 271:30375-30380.
11. Leco K.J., Apte S.S., Taniguchi G.T., et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997, 401:213-217.
12. Schulze C.J., Wang W., Suarez-Pinzon W.L., Sawicka J., Sawicki G., Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 2003, 107:2487-2492.
13. Khalil P.N., Siebeck M., Huss R., et al. Histochemical assessment of early myocardial infarction using 2,3,5-triphenyltetrazolium chloride in blood-perfused porcine hearts. JPharmacol Toxicol Methods 2006, 54:307-312.
14. Timmers L., Lim S.K., Arslan F., et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007, 1:129-137.
15. Sawicki G., Sanders E.J., Salas E., Wozniak M., Rodrigo J., Radomski M.W. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998, 80:836-839.
16. George S.J., Johnson J.L. In situ zymography. Methods Mol Biol 2010, 622:271-277.
17. Ussher J.R., Wang W., Gandhi M., et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 2012, 94:359-369.
18. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
19. He G. Electron paramagnetic resonance oximetry and redoximetry. Methods Mol Biol 2010, 594:85-105.
20. Hernandez O.M., Jones M., Guzman G., Szczesna-Cordary D. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 2007, 292:H1643-H1654.
21. Morano I., Ritter O., Bonz A., Timek T., Vahl C.F., Michel G. Myosin light chain-actin interaction regulates cardiac contractility. Circ Res 1995, 76:720-725.
22. Timson D.J. Fine tuning the myosin motor: the role of the essential light chain in striated muscle myosin. Biochimie 2003, 85:639-645.